LIXTE Biotechnology Holdings has appointed Sidney Braun as Chief Executive Officer of its Liora Technologies Europe Ltd. subsidiary. Braun brings more than 20 years of healthcare operational and strategic advisory experience to the role, having previously facilitated LIXTE's November 2025 acquisition of Liora's assets. The appointment supports LIXTE's strategy to scale the LiGHT System technology and pursue a recurring revenue model within the radiotherapy segment of cancer care.
The LiGHT System is an electronically controlled proton therapy platform designed to enhance tumor treatment. Proton therapy represents a significant advancement in radiation oncology, offering more precise targeting of tumors while minimizing damage to surrounding healthy tissue. This technology could potentially improve treatment outcomes and reduce side effects for cancer patients undergoing radiotherapy.
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical and med-tech company advancing cancer treatments. The company has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE's lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology called activation lethality that is advancing a new treatment paradigm. The company's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
The appointment of Braun to lead the European subsidiary represents a strategic move to expand LIXTE's presence in the global cancer treatment market. By establishing dedicated leadership for its European operations, the company positions itself to better serve international markets and accelerate the development and commercialization of advanced cancer therapies. This development comes as the global oncology market continues to grow, with increasing demand for more effective and targeted cancer treatments.
For investors and stakeholders, the full press release can be viewed at https://ibn.fm/9kbfE. The appointment signals LIXTE's commitment to advancing its technology platforms and expanding its operational capabilities in key international markets. As with all forward-looking statements in the pharmaceutical industry, actual results may differ from expectations due to various factors beyond management's control. Full terms of use and disclaimers applicable to all content are available at http://IBN.fm/Disclaimer.
